STRATA Skin Sciences, Inc. - SSKN
About Gravity Analytica
Recent News
- 12.09.2025 - STRATA Skin Sciences Showcases XTRAC® and TheraclearX® at TeraCILAD 2025 — Reports Early Adoption Momentum in Mexico
- 11.13.2025 - STRATA Skin Sciences Reports Third Quarter 2025 Financial Results and Provides a Corporate Update
- 11.06.2025 - STRATA Skin Sciences Announces CMS Recognition of Expanded CPT Codes for Inflammatory and Autoimmune Dermatologic Conditions with Company Anticipating Wider Excimer Adoption Ahead Of 2027 CPT Expansion
- 11.05.2025 - STRATA Skin Sciences to Report Third Quarter 2025 Financial Results on November 13, 2025 and Provide Corporate Update
- 10.28.2025 - STRATA Skin Sciences Announces COFEPRIS Clearance of TheraClear® in Mexico and First Commercial Placements
- 10.20.2025 - STRATA Skin Sciences Reinforces Market Leadership Following Key Litigation Milestones Against LaserOptek
- 10.14.2025 - Excimer Laser Demonstrates Promising Results in Treating Rare Variant of Cutaneous Lymphoma, Mycosis Fungoides
- 10.03.2025 - Marking Eczema Awareness Month – Clinical Research Validates Strata Skin Sciences’ XTRAC® Excimer Laser as a Breakthrough Therapy for Localized Atopic Dermatitis
- 10.03.2025 - Marking Eczema Awareness Month – Clinical Research Validates Strata Skin Sciences’ XTRAC® Excimer Laser as a Breakthrough Therapy for Localized Atopic Dermatitis
- 09.30.2025 - STRATA Skin Sciences Receives Continued Validation for its Personalized Approach with New Published Study Highlighting XTRAC® Excimer Laser Treatment Combined with a Topical Drug in Psoriasis
Recent Filings
- 11.18.2025 - 4 Statement of changes in beneficial ownership of securities
- 11.14.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
- 11.13.2025 - 8-K Current report
- 11.13.2025 - EX-99.1 EX-99.1
- 11.07.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
- 10.30.2025 - DEF 14A Other definitive proxy statements
- 10.20.2025 - PRE 14A Other preliminary proxy statements
- 10.16.2025 - 8-K Current report
- 10.15.2025 - 424B5 Prospectus [Rule 424(b)(5)]
- 10.14.2025 - 8-K Current report